The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to offer a greater substantial reduction in body size and enhance metabolic markers,